scholarly journals Tricky nasal mass from meek polyp to intricate papilloma: A diagnostic dilemma

2021 ◽  
Vol 4 (3) ◽  
pp. 115-118
Author(s):  
Sphoorthi Basavannaiah
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Residual Disease ◽  
Inverted Papilloma ◽  
Antrochoanal Polyp ◽  
Diagnostic Dilemma ◽  
Nasal Mass ◽  
Epithelial Growth

Inverted papilloma is a benign epithelial growth arising from the underlying stroma of the nasal cavity and paranasal sinuses. The pathogenesis of this lesion uptil date remains unclear. The tumor is known for its local invasiveness, rapid recurrence and link with malignancy. The recurrence rate of this tumor is usually too high that represents residual disease in most of the cases. Hence, it is mandate that the patient keeps a proper follow up on long term concerns. Here is one such patient, whose nasal mass seemed Antrochoanal polyp clinically but ended up as Inverted papilloma histopathologically.

Inverted papilloma of the nasal cavity and the paranasal sinuses: using CT for primary diagnosis and follow-up.

1999 ◽  
Vol 172 (2) ◽  
pp. 543-548 ◽  
Author(s):  
F Dammann ◽  
P Pereira ◽  
M Laniado ◽  
P Plinkert ◽  
H Löwenheim ◽  
...  
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Primary Diagnosis ◽  
Inverted Papilloma

Hemangiopericytoma of the Nasal Cavity: A Review of 15 Cases over a 40-Year Period

1992 ◽  
Vol 6 (6) ◽  
pp. 203-209 ◽  
Author(s):  
Kenneth V. Hughes ◽  
Michael C. Bard ◽  
Jean E. Lewis ◽  
Jan L. Kasperbauer ◽  
George W. Facer
Keyword(s):  
Local Recurrence ◽  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Clinical Course ◽  
Recurrence Rates ◽  
Long Term Follow Up ◽  
Vascular Origin ◽  
The Mean

Hemangiopericytomas are rare tumors of vascular origin most commonly found in the extremities or retroperitoneal area. When they originate from the nasal cavity and paranasal sinuses, they tend to be less aggressive and generally do not metastasize. The term “hemangiopericytoma-like lesion” has been coined for sinonasal hemangiopericytomas that display more benign histologic and growth characteristics than do those located elsewhere. Fifteen cases of hemangiopericytoma of the nasal cavity and paranasal sinuses were reviewed over the period 1951 to 1990; included are follow-up data on cases reported earlier from this institution. The clinical course, management, and outcome was evaluated and correlated with the histologic characteristics of the tumors. The recurrence rate in our series was 13.3%; the mean follow-up was 11 years. No patients died of their disease or had evidence of metastatic disease. This clinicopathologic review suggests that sinonasal hemangiopericytomas should not be classified as “hemangiopericytoma-like” lesions; rather, they should be expected to have significant local recurrence rates with low rates of distant metastasis and mortality. Long-term follow-up is essential as there can be local recurrence after many years.

Leiomyosarcoma of the Nasal Cavity and Paranasal Sinuses

1976 ◽  
Vol 85 (3) ◽  
pp. 399-403 ◽  
Author(s):  
Lloyd R. Dropkin ◽  
Chik Kwun Tang ◽  
John R. Williams
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Medical Literature ◽  
Recurrent Disease ◽  
Surgical Excision ◽  
High Rate ◽  
Term Survival ◽  
Complete Surgical Excision

A case of leiomyosarcoma of the nasal cavity and paranasal sinuses is presented along with a review of the medical literature. The clinicopathological aspects of this tumor are discussed. The mode of treatment is complete surgical excision with close follow-up due to its high rate of local recurrence. The long-term survival with recurrent disease in this case is unusual.

CT evaluation of inverted papilloma in nasal cavity and paranasal sinuses

1991 ◽  
Vol 27 (2) ◽  
pp. 206
Author(s):  
Eun Young Kim ◽  
Dong Ik Kim ◽  
Jung Ho Suh ◽  
Tae Sub Chung
Keyword(s):  
Nasal Cavity ◽  
Paranasal Sinuses ◽  
Inverted Papilloma ◽  
Ct Evaluation

scholarly journals Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Robert J. Kreitman ◽  
◽  
Claire Dearden ◽  
Pier Luigi Zinzani ◽  
Julio Delgado ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Braf Inhibitor ◽  
Nucleoside Analogs ◽  
High Rate ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Long Term Follow Up

Abstract Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). Methods Eligible patients had received ≥ 2 prior systemic therapies, including ≥ 2 purine nucleoside analogs (PNAs), or ≥ 1 PNA followed by rituximab or a BRAF inhibitor. Patients received 40 µg/kg moxetumomab pasudotox intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles. Disease response and minimal residual disease (MRD) status were determined by blinded independent central review. The primary endpoint was durable complete response (CR), defined as achieving CR with hematologic remission (HR, blood counts for CR) lasting > 180 days. Results Eighty adult patients were treated with moxetumomab pasudotox and 63% completed six cycles. Patients had received a median of three lines of prior systemic therapy; 49% were PNA-refractory, and 38% were unfit for PNA retreatment. At a median follow-up of 24.6 months, the durable CR rate (CR with HR > 180 days) was 36% (29 patients; 95% confidence interval: 26–48%); CR with HR ≥ 360 days was 33%, and overall CR was 41%. Twenty-seven complete responders (82%) were MRD-negative (34% of all patients). CR lasting ≥ 60 months was 61%, and the median progression-free survival without the loss of HR was 71.7 months. Hemolytic uremic and capillary leak syndromes were each reported in ≤ 10% of patients, and ≤ 5% had grade 3–4 events; these events were generally reversible. No treatment-related deaths were reported. Conclusions Moxetumomab pasudotox resulted in a high rate of durable responses and MRD negativity in heavily pre-treated patients with HCL, with a manageable safety profile. Thus, it represents a new and viable treatment option for patients with R/R HCL, who currently lack adequate therapy. Trial registration ClinicalTrials.gov identifier: NCT01829711; first submitted: April 9, 2013. https://clinicaltrials.gov/ct2/show/NCT01829711

Extramedullary Nasal Plasmacytoma — An Unusual Clinical Entity

1996 ◽  
Vol 75 (3) ◽  
pp. 171-173 ◽  
Author(s):  
Gordon Soo ◽  
Anthony Chan ◽  
Dennis Lam ◽  
Victor Abdullah ◽  
C. Andrew van Hasselt
Keyword(s):  
World Literature ◽  
Residual Disease ◽  
Disease Recurrence ◽  
Extramedullary Plasmacytoma ◽  
Intracranial Extension ◽  
Long Term Follow Up ◽  
Unusual Appearance

A case of extramedullary plasmacytoma with its unusual appearance is reported. This is the second reported case in world literature affecting the paranasal sinuses with intracranial extension. The role of surgery is to obtain tissue for diagnosis and to excise residual disease. Radiotherapy is the treatment of choice and long-term follow-up is necessary for monitoring disease recurrence. The overall 10-year survival is about 50%. The case is discussed with a general review of the management of this pathology.

scholarly journals Long-term follow-up of 44 patients with adenocarcinoma of the nasal cavity and sinuses primarily treated with endoscopic resection followed by radiotherapy

Head & Neck ◽  
2010 ◽  
Vol 33 (6) ◽  
pp. 898-904 ◽  
Author(s):  
Laura Van Gerven ◽  
Mark Jorissen ◽  
Sandra Nuyts ◽  
Robert Hermans ◽  
Vincent Vander Poorten
Keyword(s):  
Nasal Cavity ◽  
Endoscopic Resection ◽  
Long Term Follow Up

Feline Chondrosarcoma: A Retrospective Study of 67 Cats (1987–2005)

2008 ◽  
Vol 44 (3) ◽  
pp. 124-130 ◽  
Author(s):  
Amy C. Durham ◽  
Catherine A. Popovitch ◽  
Michael H. Goldschmidt
Keyword(s):  
Retrospective Study ◽  
Nasal Cavity ◽  
Axial Skeleton ◽  
Long Bones ◽  
Facial Bones ◽  
Definitive Evidence ◽  
The Mean

The histories of 67 cats diagnosed with chondrosarcoma (CSA) from 1987 to 2005 were reviewed. The mean age was 9.6 years, and males were 1.9 times more likely to be affected than females. Chondrosarcomas were diagnosed in the following sites: appendicular and axial skeleton, nasal cavity, facial bones, and extraskeletal sites. Of the 46 (70%) CSA associated with bone, 63% arose in long bones and 37% arose in flat bones. The remaining (30%) CSA arose in the subcutis. In cases available for follow-up (n=24), no definitive evidence of metastases was found. Cats that underwent radical surgical therapies were more likely to achieve long-term control or cure.

Sign in / Sign up

Export Citation Format

Share Document